• Resize Text
    • Small Text
    • Medium Text
    • Large Text
    • Connect

Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK

Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.

Founded in 2012, Lucis has grown to become a leading provider in the development and licensing of novel and exclusive medicines. With over a dozen products covering a variety of therapeutic areas, Lucis has established a strong portfolio that, in addition to a pipeline of innovative developments, serve the growing patient need for liquid medicines.

This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.